Semasize (Semaglutide) Injection 2mg / 1.5ml (1.34mg/ml) - 6 Disposable Needles

Semasize (Semaglutide) Injection 2 mg / 1.5 mL (1.34 mg/mL) – Detailed Dosing Guide

Introduction

Semasize (Semaglutide) Injection 2 mg / 1.5 mL (1.34 mg/mL) is a GLP-1 receptor agonist formulated for weekly subcutaneous use. Designed for individuals managing type 2 diabetes or pursuing medically supervised weight loss, this pen delivers multiple doses in one device and includes six disposable needles for convenience and hygiene. Its higher concentration allows flexible dose adjustments depending on patient needs and treatment goals.

Understanding the Concentration

With a strength of 1.34 mg/mL, each 1.5 mL pen contains a total of 2 mg of semaglutide. This enables incremental dosing, meaning patients can titrate gradually rather than jumping directly to higher doses. Accurate dose selection is essential and should always follow medical guidance.

Standard Dosing Protocol

Semaglutide treatment typically follows a gradual escalation schedule to minimize gastrointestinal side effects:

• Starting dose: 0.25 mg once weekly (usually for 4 weeks)
• Step-up dose: 0.5 mg once weekly (next 4 weeks)
• Maintenance dose: 1 mg once weekly (if tolerated and needed)

Although this specific pen contains 2 mg total, it can still be used across multiple weeks depending on how doses are measured. The gradual increase allows the body to adapt, reducing nausea and digestive discomfort.

Flexible Dosing Options

One of the advantages of Semasize 2 mg / 1.5 mL is dosing flexibility:

• Low-dose phase (0.25 mg): The pen can deliver several starter doses, making it suitable for initiation
• Intermediate dosing (0.5 mg): Common for patients stabilizing blood glucose or beginning weight loss
• Higher dosing (1 mg): Often used for stronger glycemic control and more pronounced appetite suppression

Some patients, under medical supervision, may adjust dosing intervals or remain at a lower dose longer depending on tolerance and response. The pen’s concentration allows for precise micro-adjustments if required.

Administration Guidelines

Semasize is injected subcutaneously once per week, on the same day each week. It can be administered at any time of day, with or without meals. Recommended injection sites include the abdomen, thigh, or upper arm, and rotating sites is important to avoid irritation or lipodystrophy.

Each injection should use a new disposable needle. After use, needles must be safely discarded in a sharps container.

Adjustments and Missed Doses

If a dose is missed, it should be taken within 5 days of the scheduled time. If more than 5 days have passed, the missed dose should be skipped, and the next dose taken as scheduled. Patients should not double doses.

Dose escalation may be delayed if side effects occur. Staying longer at 0.25 mg or 0.5 mg is common if nausea or appetite suppression becomes too strong.

Conclusion

Semasize (Semaglutide) Injection 2 mg / 1.5 mL offers a flexible and effective dosing structure tailored to individual patient needs. Its gradual titration approach improves tolerability while maximizing benefits in blood sugar control and weight management. Careful adherence to dosing schedules and medical supervision ensures optimal results and safety throughout treatment.